Critical Contrast: Enovis (ENOV) vs. Its Rivals

Enovis (NYSE:ENOV – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Enovis to related companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enovis and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis 1 1 10 0 2.75
Enovis Competitors 4314 10603 18404 838 2.46

Enovis currently has a consensus price target of $38.62, indicating a potential upside of 41.55%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.29%. Given Enovis’ stronger consensus rating and higher possible upside, research analysts plainly believe Enovis is more favorable than its peers.

Profitability

This table compares Enovis and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enovis -22.86% 13.23% 5.19%
Enovis Competitors -269.88% -187.36% -21.77%

Insider & Institutional Ownership

98.5% of Enovis shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Enovis and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Enovis $2.25 billion -$1.18 billion -2.96
Enovis Competitors $1.87 billion $136.27 million 5.73

Enovis has higher revenue, but lower earnings than its peers. Enovis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Enovis has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Enovis’ peers have a beta of 2.58, meaning that their average stock price is 158% more volatile than the S&P 500.

Summary

Enovis beats its peers on 9 of the 13 factors compared.

Enovis Company Profile

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.